Manufacture of inter-alpha-inhibitor (IaIp) from plasma
View Patent ↗The present invention provides compositions and pharmaceutical formulations of IaIp derived from plasma. Also provided are methods for the manufacture of the IaIp compositions and formulations, as well as method for the treatment of diseases associated with IaIp dysfunction.
1. A method for preparing an enriched Inter-alpha-Inhibitor protein (IaIp) composition from plasma, the method comprising the steps of:
(i) forming a Fraction II+III precipitate from a plasma sample by:
(a) precipitating proteins from a Cohn pool, in a first precipitation step, with between about 6% and about 10% alcohol at a pH of between about 7.0 and about 7.5 to obtain a first precipitate and a first supernatant, and
(b) precipitating proteins from the first supernatant, in a second precipitation step, with between about 20% and about 25% alcohol at a pH of between about 6.6 and about 7.2, thereby forming a Fraction II+III precipitate;
(ii) suspending the Fraction II+III precipitate to form a Fraction II+III suspension;
(iii) contacting the Fraction II+III suspension with a solid phase to remove the IaIp from the Fraction II+III suspension; and
(iv) extracting the IaIp from the solid phase, thereby preparing an enriched IaIp composition.
2. The method of claim 1 , wherein the solid phase comprises finely divided silicon dioxide (SiO 2 ).
3. The method of claim 1 , wherein the method comprises the steps of:
(i) forming a Fraction II+III precipitate from a plasma sample by:
(a) precipitating proteins from a Cohn pool, in a first precipitation step, with between about 6% and about 10% alcohol at a pH of between about 7.0 and about 7.5 to obtain a first precipitate and a first supernatant;
(b) precipitating IaIp from the first supernatant, in a second precipitation step, with between about 20% and about 25% alcohol at a pH of between about 6.6 and about 7.2, thereby forming a Fraction II+III precipitate;
(ii) suspending the Fraction II+III precipitate to form a Fraction II+III suspension;
(iii) contacting the Fraction II+III suspension with a solid phase to remove the IaIp from the Fraction II+III suspension by:
(d) mixing finely divided silicon dioxide (SiO 2 ) with the Fraction II+III suspension from step (c); and
(iv) extracting the IaIp from the solid phase by:
(e) filtering the Fraction II+III suspension with a filter press, thereby forming a filter cake and a supernatant; and
(f) extracting IaIp from the filter cake with an IaIp extraction buffer, thereby preparing an enriched IaIp composition.
4. The method of claim 1 , wherein the pH of the solution is modified after the addition of alcohol in at least one of the first precipitation step or second precipitation step by the addition of a pH modifying agent.
5. The method of claim 4 , wherein the pH of the solution is modified after the addition of alcohol in all of the precipitation steps by the addition of a pH modifying agent.
6. The method of claim 4 , wherein the addition of a pH modifying agent comprises the spray addition of a pH modifying solution.
7. The method of claim 1 , wherein the pH of a precipitation step is modified before and after the addition of alcohol, during and after the addition of alcohol, or before, during, and after the addition of alcohol.
8. The method of claim 1 , wherein the pH of a precipitation step is maintained for the entire precipitation step by continuous adjustment of the pH.
9. The method of claim 1 , wherein the step of extracting IaIp comprises re-circulating an IaIp extraction buffer through a filter press containing a Fraction II+III filter cake.
10. The method of claim 9 , wherein the IaIp extraction buffer is re-circulated through the filter press for at least about 10 minutes.
11. The method of claim 9 , wherein the IaIp extraction buffer is re-circulated through the filter press for at least about 30 minutes.
12. The method of claim 1 , wherein the pH of the IaIp extraction buffer is at least about 0.3 units different from the isoelectric point of at least one IaIp protein.
13. The method of claim 1 , wherein at least one of the precipitation steps comprises spray addition of alcohol.
14. The method of claim 1 , wherein all of the precipitation steps comprise spray addition of alcohol.
15. The method of claim 1 , further comprising a step of:
(v) precipitating impurities from the enriched IaIp composition, in an additional precipitation step, thereby forming a supernatant containing IaIp.
16. The method of claim 15 , wherein the additional precipitation step comprises precipitation with between about 10% and about 19% alcohol at a pH of between about 6.0 and about 8.0.
17. The method of claim 15 , further comprising a step of:
(vi) precipitating IaIp, in an additional precipitation step.
18. The method of claim 17 , wherein IaIp is precipitated with between about 20% and about 25% alcohol at a pH of between about 6.0 and about 8.0.
19. The method of claim 1 , further comprising the steps of:
(vii) binding IaIp from the enriched IaIp composition to an anion exchange resin; and
(viii) eluting the IaIp from the anion exchange resin with an elution buffer, thereby forming a anion exchange eluate containing IaIp.
20. The method of claim 19 , further comprising the steps of:
(ix) binding IaIp from the first eluate to a heparin affinity resin; and
(x) eluting the IaIp from the heparin affinity resin with an elution buffer, thereby forming a heparin affinity eluate containing IaIp.
21. The method of claim 1 , further comprising the steps of:
(ix) binding IaIp from the enriched IaIp composition to a heparin affinity resin; and
(x) eluting the IaIp from the heparin affinity resin with an elution buffer, thereby forming a heparin affinity eluate containing IaIp.
22. The method of claim 1 , further comprising at least one viral inactivation step.
23. The method of claim 22 , wherein the viral inactivation step comprises treatment with a solvent and/or detergent, nanofiltration, heat treatment, or incubation at low pH.
24. The method of claim 1 , wherein a single Inter-alpha-Inhibitor protein (IaIp) species is isolated.
25. The method of claim 24 , wherein the IaIp species is Inter-alpha-Trypsin Inhibitor (IaI).
26. The method of claim 24 , wherein the IaIp species is Pre-alpha-Inhibitor (PaI).
27. The method of claim 24 , wherein the IaIp species is isolated by an antibody affinity method.
28. The method of claim 3 , wherein at least one of the precipitation steps comprises spray addition of alcohol.
29. The method of claim 3 , wherein all of the precipitation steps comprise spray addition of alcohol.
30. The method of claim 3 , wherein the pH of the solution is modified after the addition of alcohol in at least one of the first precipitation step or second precipitation step by the addition of a pH modifying agent.
31. The method of claim 30 , wherein the pH of the solution is modified after the addition of alcohol in all of the precipitation steps by the addition of a pH modifying agent.
32. The method of claim 30 , wherein the addition of a pH modifying agent comprises the spray addition of a pH modifying solution.
33. The method of claim 3 , wherein the pH of a precipitation step is modified before and after the addition of alcohol, during and after the addition of alcohol, or before, during, and after the addition of alcohol.
34. The method of claim 3 , wherein the pH of a precipitation step is maintained for the entire precipitation step by continuous adjustment of the pH.
35. The method of claim 3 , wherein the step of extracting IaIp comprises re-circulating an IaIp extraction buffer through a filter press containing a Fraction II+III filter cake.
36. The method of claim 35 , wherein the IaIp extraction buffer is re-circulated through the filter press for at least about 30 minutes.
37. The method of claim 3 , wherein the pH of the IaIp extraction is at least about 0.3 units different from the isoelectric point of at least one IaIp protein.
38. The method of claim 3 , further comprising the step:
(v) precipitating impurities from the enriched IaIp composition, in an additional precipitation step, thereby forming a supernatant containing IaIp.
39. The method of claim 38 , wherein the additional precipitation step comprises precipitation with between about 10% and about 19% alcohol at a pH of between about 6.0 and about 8.0.
40. The method of claim 38 , further comprising a step of:
(vi) precipitating IaIp, in an additional precipitation step.
41. The method of claim 40 , wherein IaIp is precipitated with between about 20% and about 25% alcohol at a pH of between about 6.0 and about 8.0.
42. The method of claim 3 , further comprising the steps of:
(vii) binding IaIp from the enriched IaIp composition to an anion exchange resin; and
(viii) eluting the IaIp from the anion exchange resin with an elution buffer, thereby forming a first eluate containing IaIp.
43. The method of claim 42 , further comprising the steps of:
(ix) binding IaIp from the first eluate to a heparin affinity resin; and
(x) eluting the IaIp from the heparin affinity resin with an elution buffer, thereby forming a second eluate containing IaIp.
44. The method of claim 3 , further comprising the steps of:
(ix) binding IaIp from the enriched IaIp composition to a heparin affinity resin; and
(x) eluting the IaIp from the heparin affinity resin with an elution buffer, thereby forming a second eluate containing IaIp.
45. The method of claim 3 , further comprising at least one viral inactivation step.
46. The method of claim 45 , wherein the viral inactivation step comprises treatment with a solvent and/or detergent, nanofiltration, heat treatment, or incubation at low pH.
47. The method of claim 3 , wherein a single Inter-alpha-Inhibitor protein (IaIp) species is isolated.
48. The method of claim 47 , wherein the IaIp species is Inter-alpha-Trypsin Inhibitor (IaI).
49. The method of claim 47 , wherein the IaIp species is Pre-alpha-Inhibitor (PaI).
50. The method of claim 47 , wherein the IaIp species is isolated by an antibody affinity method.